#APICAT trial at #ACC25 #LBCT #cardioonc

🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths

Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE

#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky